Design, synthesis, and preliminary in vitro and in vivo pharmacological evaluation of 2-{4-[4-(2,5-disubstituted thiazol-4-yl)phenylethyl]piperazin-1-yl}-1,8-naphthyridine-3-carbonitriles as atypical antipsychotic agents

References

• Jablensky, A. The 100-year epidemiology of schizophrenia. Schizophr. Res. 1997, 28, 111–125.
   PubMed Web of Science ®Google Scholar
• Mueser, K.T., McGurk, S.R. Schizophrenia. Lancet 2004, 363, 2063–2072.
   PubMed Web of Science ®Google Scholar
• Lewine, R.R., Fogg, L., Meltzer, H.Y. Assessment of negative and positive symptoms in schizophrenia. Schizophr. Bull. 1983, 9, 368–376.
   PubMed Web of Science ®Google Scholar
• Marder, S.R., Wirshing, W.C., Van Putten, T. Drug treatment of schizophrenia. Overview of recent research. Schizophr. Res. 1991, 4, 81–90.
   PubMedGoogle Scholar
• Tandon, R., Jibson, M.D. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003, 28(Suppl. 1), 9–26.
   PubMed Web of Science ®Google Scholar
• Miyamoto, S., Duncan, G.E., Marx, C.E., Lieberman, J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10, 79–104.
   PubMed Web of Science ®Google Scholar
• Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., Höschl, C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20, 389–409.
   PubMed Web of Science ®Google Scholar
• Meltzer, H.Y., Matsubara, S., Lee, J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol. Bull. 1989, 25, 390–392.
   PubMed Web of Science ®Google Scholar
• Roth, B.L., Meltzer, H.Y., Khan, N. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv. Pharmacol. 1998, 42, 482–485.
   PubMedGoogle Scholar
• Lowe, J.A., III. Atypical antipsychotics based on the D2/5-HT2 ratio hypothesis. Curr. Med. Chem. 1994, 1, 50–60.
   Google Scholar
• Meltzer, H.Y., Li, Z., Kaneda, Y., Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27, 1159–1172.
   PubMed Web of Science ®Google Scholar
• Meltzer, H.Y. What’s atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 2004, 4, 53–57.
   PubMed Web of Science ®Google Scholar
• Wirshing, D.A., Wirshing, W.C., Kysar, L., Berisford, M.A., Goldstein, D., Pashdag, J., Mintz, J., Marder, S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 1999, 60, 358–363.
   PubMed Web of Science ®Google Scholar
• Owens, D.G. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996, 51, 895–930.
   PubMed Web of Science ®Google Scholar
• Cohen, D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004, 37, 1–11.
   PubMed Web of Science ®Google Scholar
• Tamminga, C.A. The promise of new drugs for schizophrenia treatment. Can. J. Psychiatry 1997, 42, 265–273.
   PubMed Web of Science ®Google Scholar
• Chandra Sekhar, K.V.G., Rao, V.S., Vyas, D.R.K., Kumar, M.M.K. Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substituted thiazol-4-yl)piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents. Bioorg. Med. Chem. Lett. 2008, 18, 6054–6057.
   PubMedGoogle Scholar
• Chandra Sekhar, K.V.G., Rao, V.S., Vyas, D.R.K., Kumar, M.M.K. Synthesis and preliminary screening of novel N-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}acetamides as potential atypical antipsychotic agents. J. Enzyme Inhib. Med. Chem. 2009, 24, 871–875.
   PubMed Web of Science ®Google Scholar
• Howard, H.R., Lowe, J.A. 3rd, Seeger, T.F., Seymour, P.A., Zorn, S.H., Maloney, P.R., Ewing, F.E., Newman, M.E., Schmidt, A.W., Furman, J.S., Robinson, G.L., Jackson, E., Johnson, C., Morrone, J. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 1996, 39, 143–148.
   PubMedGoogle Scholar
• Ariens, E.J., Beld, A.J., Rodrigues, J.M.F., Simonis, A.M. In The Receptors: A Comprehensive Treatise. O’Brien (Ed.), Plenum Press, New York, 1979, Vol. 1, p. 33.
   Google Scholar
• Mahesh, R., Perumal, R.V., Pandi, P.V. Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 5179–5181.
   PubMedGoogle Scholar
• Lowe, J.A. 3rd, Seeger, T.F., Nagel, A.A., Howard, H.R., Seymour, P.A., Heym, J.H., Ewing, F.E., Newman, M.E., Schmidt, A.W., Furman, J.S. 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 1991, 34, 1860–1866.
   PubMedGoogle Scholar
• Schmeer, C., Lima, L. Modulation of outgrowth from goldfish retinal explants by a 5-HT2 receptor agonist and [3H]ketanserin binding sites in goldfish and rabbit retina. Vision Res. 2000, 40, 33–40.
   PubMedGoogle Scholar
• Vivo, M., Lin, H., Strange, P.G. Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor. Mol. Pharmacol. 2006, 69, 226–235.
   PubMedGoogle Scholar
• Armstrong, D., Strange, P.G. Dopamine D2 receptor dimer formation: evidence from ligand binding. J. Biol. Chem. 2001, 276, 22621–22629.
   PubMedGoogle Scholar
• Costall, B., Naylor, R.J., Nohria, V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 1978, 50, 39–50.
   PubMed Web of Science ®Google Scholar
• Malick, J.B., Doren, E., Barnett, A. Quipazine-induced head-twitch in mice. Pharmacol. Biochem. Behav. 1977, 6, 325–329.
   PubMed Web of Science ®Google Scholar
• Costall, B., Naylor, R.J. Mesolimbic involvement with behavioural effects indicating antipsychotic activity. Eur. J. Pharmacol. 1974, 27, 46–58.
   PubMedGoogle Scholar
• Joshi, V.V., Muley, M.P., Balsara, J.J., Chandorkar, A.G. Effect of l-histidine pretreatment on haloperidol induced catalepsy and methamphetamine stereotypy in mice. Indian J. Pharmacol. 1979, 11, 293–300.
   Google Scholar
• Meltzer, H.Y., Matsubara, S., Lee, J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. J. Pharmacol. Exp. Ther. 1989, 251, 238–246.
   PubMed Web of Science ®Google Scholar